Company registration number 15810615 (England and Wales)
SUPREME PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
PAGES FOR FILING WITH REGISTRAR
SUPREME PHARMA LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
SUPREME PHARMA LTD
BALANCE SHEET
AS AT
31 OCTOBER 2025
31 October 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
3
2,829,841
-
0
Current assets
Cash at bank and in hand
29
1
Creditors: amounts falling due within one year
4
(1,540,365)
-
0
Net current (liabilities)/assets
(1,540,336)
1
Total assets less current liabilities
1,289,505
1
Creditors: amounts falling due after more than one year
5
(1,189,075)
-
0
Net assets
100,430
1
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
100,429
-
0
Total equity
100,430
1

For the financial year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 14 July 2026
Mr SP Patel
Director
Company registration number 15810615 (England and Wales)
SUPREME PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 2 -
1
Accounting policies
Company information

Supreme Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, England, HA5 5QA.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

Preparation of consolidated financial statements

The financial statements contain information about Supreme Pharma L td as an individual Company and do not contain consolidated financial information as the parent of a group. The Company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

1.2
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.3
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.4
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

SUPREME PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 3 -
1.5

Related Party exemption

The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
3
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
2,829,841
-
0
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 November 2024
-
Additions
2,829,841
At 31 October 2025
2,829,841
Carrying amount
At 31 October 2025
2,829,841
At 31 October 2024
-
SUPREME PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 4 -
4
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
51,863
-
0
Amounts owed to group undertakings
1,144,598
-
0
Other creditors
343,904
-
0
1,540,365
-
0
5
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
1,189,075
-
0
Creditors which fall due after five years are payable as follows:
Payable by instalments
981,624
-

The bank loans payable within and after one year are secured by way of fixed and floating charge over the following assets:
1) A Guarantee for £256,000 from the director.
2) A legal charge over Temple Pharmacy 110 Pitshanger Lane, Ealing, London, W5 1QP.

2025-10-31 2024-11-01 false false false 14 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr SP Patel 15810615 2024-11-01 2025-10-31 15810615 2025-10-31 15810615 2024-10-31 15810615 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 15810615 core:CurrentFinancialInstruments core:WithinOneYear 2024-10-31 15810615 core:Non-currentFinancialInstruments core:AfterOneYear 2025-10-31 15810615 core:Non-currentFinancialInstruments core:AfterOneYear 2024-10-31 15810615 core:CurrentFinancialInstruments 2025-10-31 15810615 core:CurrentFinancialInstruments 2024-10-31 15810615 core:ShareCapital 2025-10-31 15810615 core:ShareCapital 2024-10-31 15810615 core:RetainedEarningsAccumulatedLosses 2025-10-31 15810615 core:RetainedEarningsAccumulatedLosses 2024-10-31 15810615 bus:Director1 2024-11-01 2025-10-31 15810615 2023-11-01 2024-10-31 15810615 core:Non-currentFinancialInstruments 2025-10-31 15810615 core:Non-currentFinancialInstruments 2024-10-31 15810615 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 15810615 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 15810615 bus:FRS102 2024-11-01 2025-10-31 15810615 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 15810615 bus:FullAccounts 2024-11-01 2025-10-31 xbrli:pure xbrli:shares iso4217:GBP